ArticleClinical rheumatology2026
The imbalance of Th17/Treg cells exists in asymptomatic hyperuricemia (the early stage of gout).
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesGiven that hyperuricemia is a metabolic condition with a prolonged asymptomatic period and strong associations with gout and various metabolic disorders, we investigated the role of lymphocyte subsets in asymptomatic hyperuricemia (aHUA) and explored their potential implications for immune regulation.
methodThe study enrolled 59 male patients with aHUA, 29 with acute gout (AG), and 28 healthy male controls (HCs). Laboratory data, including blood cell counts, inflammatory markers, blood lipids, liver and renal function, and the percentage and absolute counts of lymphocytes and CD4 + T cell subpopulations in peripheral blood, were collected. We used flow cytometry to assess the peripheral blood lymphocyte subsets in these participants.
resultsThere were significant differences in GGT levels among all three groups, with the aHUA group showing the lowest value (AG vs. aHUA vs. HC, 69.00 vs. 23.00 vs. 35.50; P < 0.001). The lymphocyte subset data revealed a significant increase in the counts of helper T2 (Th2) (AG vs. aHUA vs. HC, 10.73 vs. 10.63 vs. 5.78; P < 0.001), Th17 (AG vs. aHUA vs. HC, 16.86 vs. 10.23 vs. 7.78; P < 0.001), and T suppressor (Ts) cells (AG vs. aHUA vs. HC, 669.32 vs. 655.00 vs. 488.84; P = 0.023), as well as the Th17/Treg ratio (AG vs. aHUA vs. HC, 0.44 vs. 0.37 vs. 0.26; P < 0.001) in both aHUA and AG groups. Furthermore, the increase in Th17 cells and the Th17/Treg ratio was more pronounced in the AG group. Total T cell levels were higher in both the aHUA and AG groups than in HCs, with the aHUA group showing the highest levels (statistically significant versus HCs) (AG vs. aHUA vs. HC, 1517.00 vs. 1620.00 vs. 1316.10; P < 0.001). Furthermore, the univariate regression analysis suggests that GGT [OR (95% CI) = 1.132 (1.069, 1.198), P < 0.001], Th17 [OR (95% CI) = 1.228 (1.104, 1.366), P < 0.001], and the Th17/Treg ratio [OR (95% CI) = 18.900 (1.892, 188.833), P = 0.012] are positively associated with acute gout flare. Multivariate regression analysis indicated that GGT [OR (95% CI) = 1.113 (1.049, 1.181), P < 0.001] and Th17 [OR (95% CI) = 1.235 (1.033, 1.476), P = 0.020] are positively correlated with acute gout flare.
conclusionsOur study highlights significant alterations in lymphocyte subsets in aHUA, emphasizing their potential role in the immune response and providing insights for future therapeutic strategies. Key Points • Th17 elevation and Th17/Treg imbalance in asymptomatic hyperuricemia (aHUA) suggest early immune dysregulation. • Th17 cell levels and GGT are positively associated with acute gout flares, serving as biomarkers of disease activity. • Both aHUA and gout patients show immune activation, while there were immunological differences across groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.